Cardellini M, et al. - Researchers applied a non-targeted metabolomics approach to determine novel biomarkers for cardiovascular mortality in patients with established atherosclerotic disease from the Tor Vergata Atherosclerosis Registry (TVAR). Comparisons were performed between serum baseline metabolomes of patients with atherosclerosis suffering from cardiovascular death vs control patients matched for age, gender, body mass index (BMI) and atherosclerotic disease status, who survived during the observation period. 2-hydroxycaproate, gluconate and sorbitol differed significantly in the cardiovascular mortality (CVM) group vs controls. Few metabolites were identified in this study for use as biomarkers for specific metabolic changes in the cardiovascular system in patients with established atherosclerotic disease.